Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 3Small Cell Lung Carcinoma 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 63Nivolumab 44atezolizumab 14Docetaxel 10Cyclophosphamide 10Paclitaxel 9Magnetic Resonance Spectroscopy 9Ipilimumab 9avelumab 8Specimen Handling 8durvalumab 7Radiosurgery 7Cetuximab 7spartalizumab 6Radiotherapy 6Immune Checkpoint Inhibitors 6Interleukin-2 5Carboplatin 5fludarabine 4cabozantinib 4Trastuzumab 4Sunitinib 4Psychiatric Rehabilitation 4Pemetrexed 4Oxaliplatin 4Fluorodeoxyglucose F18 4Everolimus 4Cisplatin 4Capecitabine 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Panobinostat × Thoracic × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡